Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair regrowth after 100 days using 5mg Minoxidil and 0.5mg Dutasteride, focusing on changes in the temples and hairline. Users debate the effectiveness due to inconsistent photo comparisons.

RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

A user shared their 7-month progress on hair regrowth using a regimen of dutasteride, minoxidil, stemoxydine, microneedling, and keto shampoo. They noted significant improvement, particularly in vellus hair growth, and discussed the potential addition of RU58841, though they experienced side effects with it previously.

RU58841 may still be potent after being left unopened for four months if protected from light and air. A user reported hair improvement using RU58841 with minoxidil, without major shedding, over 2.5 years.

User considers making Zix topical solution with ethanol/alcohol for hair loss treatment. Asks if crushing b6 and zinc into stemoxydine is possible.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

OP shared progress pictures 8 months after FUE surgery in Korea by Dr. Hyun, using Dutasteride. Users discussed the use of Dutasteride over Finasteride in Korea.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

A user shared their 15-month hair regrowth progress using finasteride, minoxidil, biotin, increased protein intake, and derma rolling. They also improved their lifestyle by working out, quitting smoking, drinking less, and getting better sleep.

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

A long-term finasteride user is considering switching to dutasteride due to hair loss progression. Users share experiences with switching, noting side effects and varying effectiveness, with some experiencing shedding and others maintaining their hairline.

The conversation discusses a person's hair regrowth after using dutasteride for 40 days and topical minoxidil for 55 days, along with weekly dermarolling. They are considering switching to oral minoxidil and asking about potential recovery.

A six month update of the users' experience with Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841.

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.

The conversation is about a user planning to undergo a hair transplant and seeking information on clinics that perform Verteporfin treatment. A user suggests Dr. Barghouthi might offer this service.

Long-term RU58841 users discuss its effectiveness, with some finding it not worth the cost compared to other treatments like Dutasteride and Minoxidil. One user experienced side effects from a chemical company product, while another is regrowing hair after stopping RU58841.

The user reports positive results from using 0.5 mg dutasteride daily for four months and 2.5 mg oral minoxidil for three months, with no side effects. They switched from topical minoxidil to this oral combination.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

A user shared progress pictures showing improvement from NW 6 to NW 2 after four months of treatment. They are considering using exosomes to further reverse hair miniaturization.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

RU58841 cured seborrheic dermatitis, oily scalp, dandruff, and scalp pain, improving hair health when combined with Minoxidil. Another user noted diet impacts their seborrheic dermatitis and that finasteride hasn't changed their condition.

A 46-year-old male shared his 3-week progress using HIMS serum with Finasteride 0.3% and Minoxidil 6%, showing improvement without noticeable shedding. His routine includes vitamins, a healthy diet, and specific hair care practices like microneedling and using caffeine solution.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.